SMS Lifesciences India Limited (SMSLIFE.BO)
INR 1350.85
(2.06%)
INR 1350.85
(2.06%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 359.47 Million INR | -6.71% |
| 2022 | 173.38 Million INR | -23.07% |
| 2021 | 225.38 Million INR | -8.73% |
| 2020 | 246.93 Million INR | 82.93% |
| 2019 | 134.98 Million INR | -43.79% |
| 2018 | 240.15 Million INR | 605.25% |
| 2017 | 34.05 Million INR | -82.38% |
| 2016 | 193.24 Million INR | 1044651.35% |
| 2015 | -18.5 Thousand INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 126.05 Million INR | 144.38% |
| 2023 Q3 | 55.67 Million INR | 34.8% |
| 2023 FY | 161.75 Million INR | -6.71% |
| 2023 Q2 | 41.29 Million INR | 454.58% |
| 2023 Q1 | -11.64 Million INR | -82.44% |
| 2023 Q4 | 75.76 Million INR | 36.1% |
| 2022 Q2 | 56.29 Million INR | -4.57% |
| 2022 Q3 | 67.28 Million INR | 19.53% |
| 2022 Q4 | -6.38 Million INR | -109.49% |
| 2022 Q1 | 58.99 Million INR | 53.03% |
| 2022 FY | 173.38 Million INR | -23.07% |
| 2021 Q4 | 38.54 Million INR | -34.06% |
| 2021 FY | 225.38 Million INR | -8.73% |
| 2021 Q2 | 69.2 Million INR | 13.85% |
| 2021 Q1 | 60.78 Million INR | -5.81% |
| 2021 Q3 | 58.46 Million INR | -15.53% |
| 2020 Q2 | 62.82 Million INR | 32.25% |
| 2020 FY | 246.93 Million INR | 82.93% |
| 2020 Q1 | 47.5 Million INR | 106.27% |
| 2020 Q3 | 53.33 Million INR | -15.11% |
| 2020 Q4 | 64.53 Million INR | 21.01% |
| 2019 Q2 | 72.91 Million INR | -14.13% |
| 2019 FY | 134.98 Million INR | -43.79% |
| 2019 Q4 | 23.03 Million INR | 120.25% |
| 2019 Q3 | 10.45 Million INR | -85.66% |
| 2019 Q1 | 84.9 Million INR | 17.32% |
| 2018 Q1 | 55.75 Million INR | 270.37% |
| 2018 FY | 240.15 Million INR | 605.25% |
| 2018 Q4 | 72.37 Million INR | -32.96% |
| 2018 Q3 | 107.96 Million INR | 45.28% |
| 2018 Q2 | 74.31 Million INR | 33.29% |
| 2017 Q3 | 41.14 Million INR | 107.49% |
| 2017 Q4 | 15.05 Million INR | -63.42% |
| 2017 FY | 34.05 Million INR | -82.38% |
| 2017 Q1 | 29.47 Million INR | -45.6% |
| 2017 Q2 | 19.83 Million INR | -32.72% |
| 2016 Q1 | 73.89 Million INR | 0.0% |
| 2016 Q3 | 75.64 Million INR | 78.97% |
| 2016 Q2 | 42.26 Million INR | -42.8% |
| 2016 FY | 193.24 Million INR | 1044651.35% |
| 2016 Q4 | 54.18 Million INR | -28.37% |
| 2015 FY | -18.5 Thousand INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 9.28 Million INR | -3772.369% |
| Biocon Limited | 50.83 Billion INR | 99.293% |
| Blue Jet Healthcare Limited | 3.37 Billion INR | 89.34% |
| Concord Biotech Limited | 6.26 Billion INR | 94.259% |
| Dishman Carbogen Amcis Limited | -13.9 Million INR | 2686.129% |
| FERMENTA BIOTECH LIMITED | 1.06 Billion INR | 66.34% |
| GENOMIC VALLEY BIOTECH LIMITED | 1.27 Million INR | -28077.307% |
| Lyka Labs Limited | 29.13 Million INR | -1134.027% |
| Panacea Biotec Limited | -309.7 Million INR | 216.071% |
| SAMSRITA LABS LIMITED | -1.49 Million INR | 24106.732% |
| Servoteach Industries Limited | -785.00 INR | 45792711.465% |
| Supriya Lifescience Limited | 1.57 Billion INR | 77.128% |
| Syngene International Limited | 14.02 Billion INR | 97.437% |
| TAKE Solutions Limited | -213.49 Million INR | 268.379% |
| Titan Biotech Limited | 315.89 Million INR | -13.794% |
| Transgene Biotek Limited | -7.08 Million INR | 5170.842% |
| Vanta Bioscience Limited | -31.83 Million INR | 1229.066% |